Flexeril
This article was originally published in The Tan Sheet
Executive Summary
OTC rights retained by Merck under transaction divesting Rx sales and marketing rights for the muscle relaxant and exclusive trademark rights in the U.S. and Canada to Alza. Merck receives up-front and milestone payments under deal. Alza currently is developing a once-a-day formulation of cyclobenzaprine. Merck says it is continuing discussions with FDA about switching Flexeril OTC. In July 1999, NDAC expressed concerns about patients' ability to accurately detect when to use OTC Flexeril 5 mg but did not take a formal vote on a switch (1"The Tan Sheet" July 26, 1999, p. 3)